The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and more. The Federal Trade Commission is challenging ...
What Happened: The FTC is disputing “junk patent listings” for diabetes, weight loss, asthma and COPD drugs. This initiative represents the latest endeavor against what the agency perceives as ...
The cost of drugs in the U.S. continues to skyrocket. The average drug price increase from 2022 to 2023 was 15%, according to ...
The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with the FDA. After an initial round of challenges launched in November ...
The Federal Trade Commission is challenging more than 300 patents filed with the Food and Drug Administration to protect market exclusivity for top-selling drugs. The patents cover 20 brand-name ...
FTC targets 300 Big Pharma 'junk patents,' sends warning letters to top drugmakers The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book ...
The FTC recently announced that it has sent another round of letters disputing additional patent listings in the FDA’s Orange Book. With this latest action, the FTC has now challenged hundreds ...
Federal antitrust officials have redoubled efforts to challenge what they see as improper pharma patent listings that delay the market entry of generic drugs. This week, the Federal Trade Commission ...
The Federal Trade Commission sent letters to 10 drugmakers April 30 warning them that hundreds of patent listings for 20 drugs are invalid. The agency said "junk" listings keep drug prices high by ...
The move targets over 300 listings for 20 branded products from companies such as AstraZeneca, Novo Nordisk, and GSK that the agency said inhibits the generic drug market. The Federal Trade Commission ...
At the center of the issue is the Orange Book, an FDA publication containing patents relevant to brand-name pharmaceuticals. If a brand-name manufacturer decides to contest a challenge to an ...